FREMONT, Calif., Oct. 3 /PRNewswire-FirstCall/ -- Protein Design Labs,
Inc. (PDL) (Nasdaq: PDLI) today announced that it will conduct a live webcast
of its R&D Update presentation to the financial community. The live webcast
will begin at 8:00 a.m. Eastern Daylight Time on October 7, and is expected to
conclude by 11:00 a.m. Eastern Daylight Time.
Steven Benner, M.D., Senior Vice President and Chief Medical Officer, PDL,
will host the R&D Update and webcast. Joining him from the company will be
Richard Murray, Ph.D., Senior Vice President, Chief Scientific and Technical
Officer.
In addition, presentations by leading physicians in the areas of liver
disease, ulcerative colitis and heart failure will be made as follows:
Samuel Sigal, M.D., Center for Liver Disease and Transplantation, Weill
Cornell Medical Center, New York, will discuss research on terlipressin for
the treatment of type I hepatorenal syndrome.
Lloyd F. Mayer, M.D., Professor and Director of the Center for
Immunobiology at The Mount Sinai Hospital, New York, will discuss current
research on Nuvion(R) (visilizumab) for the treatment of intravenous steroid-
refractory ulcerative colitis.
Markus Meyer, M.D., co-founder and Managing Director of Cardiopep Pharma
GmbH, Hannover, Germany will review the development and early research on
ularitide for the treatment of acute decompensated heart failure.
Veselin Mitrovic, M.D., Medical Director of the Research Unit / Kerckhoff
Clinic, Bad Nauheim, Germany, will present the recently announced SIRIUS II
data on ularitide for the treatment of acute decompensated heart failure.
Dr. Benner will update the clinical development plans and timelines for
PDL's products in development, including visilizumab, ularitide, daclizumab,
volociximab and HuZAF(TM) (fontolizumab). Dr. Murray will present a summary
of PDL's ongoing antibody discovery and research efforts.
The live webcast will be available through the PDL website: http://www.pdl.com.
Please connect to this website at least 15 minutes prior to the live webcast
to allow time for any software download that may be needed to hear the
webcast. A replay, including the presentation materials, will be available at
http://www.pdl.com starting approximately one hour after completion of the webcast.
PDL's Second Annual R&D Update will take place at the Four Seasons Hotel,
Cosmopolitan Room, 57 East 57th Street, New York, NY 10022. Additional
information on attending the Update can be obtained by contacting Jade Cantor
at (212) 843-0211 or jcantor@lazarpartners.com
About Protein Design Labs
PDL is a biopharmaceutical company focused on the research, development
and commercialization of novel therapies for inflammation and autoimmune
diseases, acute cardiac conditions and cancer. PDL markets several products
in the United States through its hospital sales force and wholly-owned
subsidiary, ESP Pharma, Inc. As a leader in the development of humanized
antibodies, PDL has licensed its patents to numerous pharmaceutical and
biotechnology companies, some of which are now paying royalties on net sales
of licensed products. Further information on PDL is available at http://www.pdl.com.
Protein Design Labs, the PDL logo and Nuvion are registered U.S.
trademarks and HuZAF is a trademark of Protein Design Labs, Inc.
SOURCE Protein Design Labs, Inc.
 back to top
Related links:
http://www.pdl.com
CONTACT:
James R. Goff, Sr. Director, Investor
Relations, of Protein Design Labs, Inc., +1-510-574-1421 or
jgoff@pdl.com, or Jade Cantor of Lazar Partners, +1-212-843-0211
or jcantor@lazarpartners.com, for Protein Design Labs, Inc.
|
